SCHEMBL4345360

SCHEMBL4345360

Cc1ccc(C(=O)OC(C)(C)C)s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.53
ALDH1A1 P00352 8/20 0.46
POLB P06746 5/20 0.46
HPGD P15428 3/20 0.46
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
RAB9A P51151 3/20 0.43
TDP1 Q9NUW8 3/20 0.42
KMT2A Q03164 3/20 0.42
L3MBTL1 Q9Y468 3/20 0.41
LMNA P02545 2/20 0.41
RECQL P46063 2/20 0.41
GAA P10253 1/20 0.41
GRM6 O15303 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40
KDM4E B2RXH2 2/20 0.40
MAPT P10636 2/20 0.40
NPC1 O15118 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8549434 0.88 TSHR (0.44) DAOALDH1A1HPGDTDP1L3MBTL1
SCHEMBL16942053 0.83 ALDH1A1 (0.39) DAOALDH1A1POLBHPGDCASP3
SCHEMBL5919206 0.81 LMNA (0.53) ALDH1A1HPGDRAB9AL3MBTL1LMNA
SCHEMBL8549436 0.81 DAO (0.48) DAOALDH1A1POLBHPGDRAB9A
SCHEMBL6832829 0.80 ALDH1A1 (0.46) DAOALDH1A1POLBHPGDCASP3
SCHEMBL7651751 0.79 DAO (0.61) DAOALDH1A1POLBHPGDCASP3
SCHEMBL5043396 0.79 CES2 (0.53) DAOALDH1A1POLBHPGDCASP3
SCHEMBL17900427 0.79 GRM6 (0.43) ALDH1A1HPGDL3MBTL1LMNAGAA
SCHEMBL425794 0.78 DAO (0.65) DAOALDH1A1POLBHPGDCASP3
SCHEMBL23791955 0.77 ALDH1A1 (0.38) DAOALDH1A1HPGDL3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 US disclosed
WO-2020216919-A1 ARYLSULFONYLTHIOPHENECARBOXAMIDES AND ARYLSULFONYLFURANCARBOXAMIDES AS Kν3 POTASSIUM CHANNEL ACTIVATORS H. LUNDBECK A/S (DK) 2020-10-29 WO disclosed
US-9199927-B2 Guanidinobenzoic acid compound ASTELLAS PHARMA INC. (JP) 2015-12-01 US disclosed
EP-2024390-B1 INSULIN DERIVATIVE NOVO NORDISK AS (DK) 2015-08-19 EP disclosed
EP-2024390-B1 INSULIN DERIVATIVE NOVO NORDISK AS (DK) 2015-08-19 EP disclosed
US-20140378459-A1 GUANIDINOBENZOIC ACID COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-25 US disclosed
US-8796205-B2 Insulin derivative NOVO NORDISK A/S (DK) 2014-08-05 US disclosed
US-8796205-B2 Insulin derivative NOVO NORDISK A/S (DK) 2014-08-05 US disclosed
US-8796205-B2 Insulin derivative NOVO NORDISK A/S (DK) 2014-08-05 US disclosed
US-20090105121-A1 Insulin Derivative NOVO NORDISK A/S (DK) 2009-04-23 US disclosed
US-20090105121-A1 Insulin Derivative NOVO NORDISK A/S (DK) 2009-04-23 US disclosed
US-20090105121-A1 Insulin Derivative NOVO NORDISK A/S (DK) 2009-04-23 US disclosed
EP-2024390-A1 INSULIN DERIVATIVE Novo Nordisk A/S (DK) 2009-02-18 EP disclosed
WO-2007128815-A1 INSULIN DERIVATIVE NOVO NORDISK A/S (DK) 2007-11-15 WO disclosed
WO-2007128815-A1 INSULIN DERIVATIVE NOVO NORDISK A/S (DK) 2007-11-15 WO disclosed
CN-1070402-A The pyrimidine derivatives of condensation EISAI CO LTD (JP) 1993-03-31 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105121-A1 Insulin Derivative INSR, IAPP, GPR119 DAO 3702/4885ALDH1A1 4606/4885POLB 4633/4885
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 DAO 3614/4885ALDH1A1 4776/4885POLB 1778/4885
US-11753403-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 DAO 3614/4885ALDH1A1 4776/4885POLB 1778/4885
US-20140378459-A1 GUANIDINOBENZOIC ACID COMPOUND SERPINB1, REN, SPINT2 DAO 157/4885ALDH1A1 2023/4885POLB 3503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.